CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+16%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$70.4K
Cap. Flow
% of AUM
-0.02%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
244
Closed
13
Top Buys
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.28M |
| 2 |
Tesla
TSLA
|
$2.24M |
| 3 |
Apple
AAPL
|
$2.14M |
| 4 |
Meta Platforms (Facebook)
META
|
$2.1M |
| 5 |
Vaxcyte
PCVX
|
$2M |
Top Sells
| 1 |
iQIYI
IQ
|
$4.85M |
| 2 |
Amazon
AMZN
|
$4.7M |
| 3 |
Airbnb
ABNB
|
$3.2M |
| 4 |
Analog Devices
ADI
|
$2.94M |
| 5 |
KE Holdings
BEKE
|
$1.93M |
Sector Composition
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
HilleVax
HLVX
$105M
| $8.84K | ﹤0.01% |
514
+62
| +14% | +$1.07K |
|
|
BCYC
327
Bicycle Therapeutics
BCYC
$483M
| $8.65K | ﹤0.01% |
339
-10
| -3% | -$255 |
|
328
Anavex Life Sciences
AVXL
$807M
| $8.61K | ﹤0.01% |
1,059
+2
| +0.2% | +$16 |
|
329
Dyne Therapeutics
DYN
$2.02B
| $8.6K | ﹤0.01% |
764
+58
| +8% | +$653 |
|
330
RAPT Therapeutics
RAPT
$214M
| $8.42K | ﹤0.01% |
56
-2
| -3% | -$301 |
|
331
Novavax
NVAX
$1.28B
| $8.4K | ﹤0.01% |
1,131
-36
| -3% | -$267 |
|
332
ARS Pharmaceuticals
SPRY
$995M
| $8.32K | ﹤0.01% |
1,242
-28
| -2% | -$188 |
|
333
Seres Therapeutics
MCRB
$169M
| $8.03K | ﹤0.01% |
84
| – | – |
|
334
Theravance Biopharma
TBPH
$703M
| $7.84K | ﹤0.01% |
757
-156
| -17% | -$1.62K |
|
335
Arcutis Biotherapeutics
ARQT
$2.06B
| $7.67K | ﹤0.01% |
805
-23
| -3% | -$219 |
|
336
Harrow
HROW
$1.37B
| $7.52K | ﹤0.01% |
395
-8
| -2% | -$152 |
|
337
Editas Medicine
EDIT
$248M
| $7.45K | ﹤0.01% |
905
-30
| -3% | -$247 |
|
|
MRNS
338
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $7.19K | ﹤0.01% |
662
-10
| -1% | -$109 |
|
339
AnaptysBio
ANAB
$613M
| $7.06K | ﹤0.01% |
347
-38
| -10% | -$773 |
|
|
ME
340
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $6.72K | ﹤0.01% |
192
-4
| -2% | -$140 |
|
|
TSVT
341
DELISTED
2seventy bio
TSVT
| $6.66K | ﹤0.01% |
658
+145
| +28% | +$1.47K |
|
342
Alector
ALEC
$305M
| $6.57K | ﹤0.01% |
1,093
-32
| -3% | -$192 |
|
343
Terns Pharmaceuticals
TERN
$632M
| $6.5K | ﹤0.01% |
743
+72
| +11% | +$630 |
|
|
ALPN
344
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $6.47K | ﹤0.01% |
629
+6
| +1% | +$62 |
|
345
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $6.45K | ﹤0.01% |
458
-10
| -2% | -$141 |
|
346
Edgewise Therapeutics
EWTX
$1.64B
| $6.43K | ﹤0.01% |
829
-28
| -3% | -$217 |
|
347
Tarsus Pharmaceuticals
TARS
$2.43B
| $6.36K | ﹤0.01% |
352
-10
| -3% | -$181 |
|
348
Nautilus Biotechnolgy
NAUT
$83.5M
| $6.34K | ﹤0.01% |
1,637
-55
| -3% | -$213 |
|
349
Nurix Therapeutics
NRIX
$758M
| $6.21K | ﹤0.01% |
622
-19
| -3% | -$190 |
|
|
ITOS
350
DELISTED
iTeos Therapeutics
ITOS
| $6.21K | ﹤0.01% |
469
-13
| -3% | -$172 |
|